J Am Pharm Assoc (2003). 2020 Jan-Feb;60(1):212-215. doi: 10.1016/j.japh.2019.09.012. Epub 2019 Nov 6.
Cannabis sativa was introduced in Latin America in the 16th century. Nevertheless, many years have elapsed, and scientific progress and the medicinal use of C sativa have been restricted by the national laws of the countries in the region.
In Argentina, the first law on medical cannabis, approved in 2017 (#17,350), establishes a regulatory framework for the medical use and scientific research of this plant and its derivatives. In 2018, the first clinical research protocol in Latin America was approved at Hospital de Pediatria Garrahan (Buenos Aires, Argentina) to evaluate the efficacy and safety of cannabidiol (CBD) oil for the treatment of pediatric patients with refractory epilepsy. In this context, the role of pharmacists in the health care system related to the study protocol and the medicinal use of CBD has evolved from dispensing to active participation in clinical follow-up and research protocols.
Considering this experience, here we discuss the active role of the clinical pharmacist in the use of medicinal cannabis. Medicinal cannabis should be controlled in a legal framework based on clinical evidence, and the participation of the pharmacist in research and clinical protocols, as well as the dispensing and provision of information on the medicinal products should be emphasized in the clinical setting.
大麻于 16 世纪被引入拉丁美洲。然而，多年过去了，该地区各国的国家法律限制了大麻的科学研究进展和药用。
阿根廷于 2017 年通过了第一部关于医用大麻的法律 (#17,350)，为该植物及其衍生物的医用和科学研究建立了监管框架。2018 年，在阿根廷布宜诺斯艾利斯的儿童 Garrahan 医院批准了拉丁美洲的第一个临床研究方案，以评估大麻二酚 (CBD) 油治疗难治性癫痫儿童患者的疗效和安全性。在这种情况下，药剂师在与研究方案和 CBD 药用相关的医疗保健系统中的作用已经从配药演变为积极参与临床随访和研究方案。
鉴于这一经验，我们在这里讨论了临床药剂师在医用大麻使用中的积极作用。医用大麻应在基于临床证据的法律框架内进行管制，药剂师应参与研究和临床方案，并在临床环境中强调配药和提供有关药品的信息。
